Skip to main content
SpringerLink
Log in

Effect of hyperglycemic condition on proteoglycan secretion in cultured human endothelial cells

  • ORIGINAL CONTRIBUTION
  • Published:
European Journal of Nutrition Aims and scope Submit manuscript

Abstract

Background

Proteoglycans (PGs) are important constituents of the plasma membrane and of the basement membrane supporting the endothelial cell layer. Changes in the amounts or the structures of PGs in the endothelium may affect important functions such as turnover of lipoproteins, filtration properties, and regulation of chemokines during inflammation, which are all relevant in diabetes.

Aim of the study

The purpose of this study was to investigate if hyperglycemic conditions would affect the biosynthesis and secretion of PGs in cultured primary human endothelial cells.

Methods

Primary human umbilical cord vein endothelial cells were established and cultured in vitro. The cells were cultured either in medium with low glucose (LG) (1 g/l) or high glucose (HG) (4.5 g/l). From day 3–4 cells were labeled with 35S-sulfate for 24 h. 35S-Labeled macromolecules (medium) were purified by gel chromatography, and isolated macromolecules were analyzed by gel chromatography after different types of treatment, electrophoresis, and immunoprecipitation.

Results

Lower levels of secreted PGs were found in human endothelial cells exposed to HG. The major part of the PGs released was of the heparan sulfate (HS) type, and immunoprecipitation experiments showed that one such PG was syndecan-1. However, there was no difference in the ratio between HS and chondroitin sulfate (CS) under the different experimental conditions. Further, the PGs expressed neither differ with regard to molecular size of the glycosaminoglycan (GAG) chains, nor were their polyanionic properties affected by the different experimental conditions.

Conclusion:

The results obtained suggest that treatment of primary human endothelial cells with hyperglycemia leads to a decrease in PG secretion in primary cultures of human endothelial cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. The Diabetes Control, Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986

    Article  Google Scholar 

  2. Yamagishi S, Imaizumi T (2005) Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm 11(18):2279–2299

    Article  CAS  Google Scholar 

  3. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820

    Article  CAS  Google Scholar 

  4. Selleck SB (2000) Proteoglycans and pattern formation: sugar biochemistry meets developmental genetics. Trends Genet 16(5):206–212

    Article  CAS  Google Scholar 

  5. Kjellen L, Lindahl U (1991) Proteoglycans: structures and interactions. Annu Rev Biochem 60:443–475

    Article  CAS  Google Scholar 

  6. Kolset SO, Salmivirta M (1999) Cell surface heparan sulfate proteoglycans and lipoprotein metabolism. Cell Mol Life Sci 56:857–870

    Article  CAS  Google Scholar 

  7. Miner JH (1999) Renal basement membrane components. Kidney Int 56:2016–2024

    Article  CAS  Google Scholar 

  8. Saku T, Furthmayr H (1989) Characterization of the major heparan sulfate proteoglycan secreted by bovine aortic endothelial cells in culture. Homology to the large molecular weight molecule of basement membranes. J Biol Chem 264:3514–3523

    CAS  Google Scholar 

  9. Iozzo RV (1998) Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 67:609–652

    Article  CAS  Google Scholar 

  10. Rops AL, van der Vlag J, Lensen JF, et al. (2004) Heparan sulfate proteoglycans in glomerular inflammation. Kidney Int 65:768–785

    Article  CAS  Google Scholar 

  11. Wang L, Fuster M, Sriramarao P, Esko JD (2005) Endothelial heparan sulfate deficiency impairs l-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat Immunol 6:902–910

    Article  CAS  Google Scholar 

  12. Bollineni JS, Alluru I, Reddi AS (1997) Heparan sulfate proteoglycan synthesis and its expression are decreased in the retina of diabetic rats. Curr Eye Res 16:127–130

    Article  CAS  Google Scholar 

  13. Laffont I, Shuvaev VV, Briand O, et al. (2002) Early-glycation of apolipoprotein E: effect on its binding to LDL receptor, scavenger receptor A and heparan sulfates. Biochim Biophys Acta 1583:99–107

    CAS  Google Scholar 

  14. Vogl-Willis CA, Edwards IJ (2004) High-glucose-induced structural changes in the heparan sulfate proteoglycan, perlecan, of cultured human aortic endothelial cells. Biochim Biophys Acta 1672:36–45

    CAS  Google Scholar 

  15. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A (1989) Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 32:219–226

    Article  CAS  Google Scholar 

  16. Jensen T (1997) Pathogenesis of diabetic vascular disease: evidence for the role of reduced heparan sulfate proteoglycan. Diabetes 46(Suppl 2):S98–S100

    CAS  Google Scholar 

  17. Kjellen L, Bielefeld D, Hook M (1983) Reduced sulfation of liver heparan sulfate in experimentally diabetic rats. Diabetes 32:337–342

    CAS  Google Scholar 

  18. Ha TS, Song CJ, Lee JH (2004) Effects of advanced glycosylation endproducts on perlecan core protein of glomerular epithelium. Pediatr Nephrol 19:1219–1224

    Article  Google Scholar 

  19. Vogl-Willis CA, Edwards IJ (2004) High glucose-induced alterations in subendothelial matrix perlecan leads to increased monocyte binding. Arterioscler Thromb Vasc Biol 24:858–863

    Article  CAS  Google Scholar 

  20. Shively JE, Conrad HE (1976) Formation of anhydrosugars in the chemical depolymerization of heparin. Biochemistry (Mosc) 15:3932–3942

    Article  CAS  Google Scholar 

  21. Jarvelainen HT, Kinsella MG, Wight TN, Sandell LJ (1991) Differential expression of small chondroitin/dermatan sulfate proteoglycans, PG-I/ biglycan and PG-II/decorin, by vascular smooth muscle and endothelial cells in culture. J Biol Chem 266:23274–23281

    CAS  Google Scholar 

  22. Edwards IJ, Wagner JD, Vogl-Willis CA, Litwak KN, Cefalu WT (2004) Arterial heparan sulfate is negatively associated with hyperglycemia and atherosclerosis in diabetic monkeys. Cardiovasc Diabetol 3:6

    Article  Google Scholar 

  23. Nugent MA, Iozzo RV (2000) Fibroblast growth factor-2. Int J Biochem Cell Biol 32:115–120

    Article  CAS  Google Scholar 

  24. Garin EH, Shirey AJ (1988) Glomerular basement membrane heparan sulfate glycosaminoglycan in aminonucleoside of puromycin nephrosis. Child Nephrol Urol 9:121–126

    Google Scholar 

  25. Sorensson J, Bjornson A, Ohlson M, Ballermann BJ, Haraldsson B (2003) Synthesis of sulfated proteoglycans by bovine glomerular endothelial cells in culture. Am J Physiol Renal Physiol 284:F373–F380

    CAS  Google Scholar 

  26. Borrebæk J, Prydz K, Fjeldstad K, et al. (2001) The AGE product N epsilon-(carboxymethyl)lysine serum albumin is a modulator of proteoglycan expression in polarized cultured kidney epithelial cells. Diabetologia 44:488–494

    Article  Google Scholar 

  27. Osawa T, Kato Y (2005) Protective role of antioxidative food factors in oxidative stress caused by hyperglycemia. Ann NY Acad Sci 1043:440–451

    Article  CAS  Google Scholar 

  28. Way KJ, Isshiki K, Suzuma K, et al. (2002) Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes 51:2709–2718

    CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by grants from Helse og Rehabilitering, Norges Diabetsforbund, and the Throne Holst Foundation.

Author information

Author notes

  1. Sedegheh Gharagozlian

    Present address: Aker University Hospital, Trondheimsveien 235, Oslo, Norway

Authors and Affiliations

  1. Dept. of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Box 1046, Blindern, 0316, Oslo, Norway

    Sedegheh Gharagozlian, Jørgen Borrebæk, Tone Kristin Omsland, Hamid Shegarfi & Svein Olav Kolset

  2. Rikshospitalet University Hospital, Oslo, Norway

    Tore Henriksen

Authors
  1. Sedegheh Gharagozlian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jørgen Borrebæk
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tore Henriksen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tone Kristin Omsland
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hamid Shegarfi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Svein Olav Kolset
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sedegheh Gharagozlian.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gharagozlian, S., Borrebæk, J., Henriksen, T. et al. Effect of hyperglycemic condition on proteoglycan secretion in cultured human endothelial cells. Eur J Nutr 45, 369–375 (2006). https://doi.org/10.1007/s00394-006-0608-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00394-006-0608-9

Keywords

Search

Navigation